Nature Communications · 2025 · 20 citations · 27 references
MedicineMolecular BiologyOncologyCancer GeneticsMolecular OncologyNeoplasiaCancer Cell SignalingCancer GenomicsColorectal CancerOncogenic Signaling PathwaysReceptor Tyrosine Kinase OncogenesSignal Transduction In CancerCancer Signaling PathwaysEgfr InhibitionGenome-wide Crispr ScreeningGlutathione Peroxidase 4Mapk SignalingMitogen-activated Protein Kinase SignalingPolo-like Kinase InhibitionTherapeutic Resistance Mechanisms
Metastatic BRAFV600E colorectal cancer (CRC) confers poor prognosis and represents a therapeutic bottleneck. To identify resistance mechanisms of the mitogen-activated protein kinase (MAPK) pathway in BRAFV600E CRC, we perform genome-wide CRISPR-Cas9 screening and discover that targeting glutathione peroxidase 4 (GPX4) overcomes resistance to BRAF inhibitor (BRAFi) combined with or without epidermal growth factor receptor inhibitor (EGFRi) in BRAFV600E CRC. Specifically, BRAFi ± EGFRi upregulates GPX4 expression, which antagonizes therapy-induced ferroptosis. Moreover, polo-like kinase 1 (PLK1) substrate activation promotes PLK1 translocation to the nucleus, activating chromobox protein homolog 8 (CBX8) phosphorylation at Ser265 to drives GPX4 expression. Targeting PLK1 enhances BRAFi ± EGFRi inhibition and triggers ferroptosis in vitro, vivo, organoid, and patient-derived xenograft model. Collectively, we demonstrate a PLK1–CBX8–GPX4 signaling axis that relays the ferroptosis mechanism of therapeutic resistance and propose a clinically actionable strategy to overcome BRAFi ± EGFRi resistance in BRAFV600E CRC. Dual targeting of BRAF and MAPK signaling in the BRAF v600E mutant colorectal cancer patients has shown limited efficacy in clinical studies. Here, the authors identify PLK1 inhibition as synthetic lethal with dual BRAF and EGFR inhibition due to loss of ferroptosis inhibition via a PLK1-CBX8-GPX4 signaling axis in preclinical models of colorectal cancer.
27
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem, Neville E. Sanjana, Ella Hartenian et al. · Science · 2013 · 5.5K citations · Full text
Colorectal cancer statistics, 2023
Rebecca L. Siegel, Nikita Sandeep Wagle, Andrea Cercek et al. · CA A Cancer Journal for Clinicians · 2023 · 3.8K citations · Full text
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad, Chong Sun, Sidong Huang et al. · Nature · 2012 · 2.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Vasanthi S. Viswanathan, Matthew J. Ryan, Harshil Dhruv et al. · Nature · 2017 · 2K citations · Full text
Medicine, Cancer Biology, Oncology +16
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
Nicholas Yagoda, Moritz von Rechenberg, Elma Zaganjor et al. · Nature · 2007 · 1.6K citations · Full text